Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Nancy Dvorin
In Vivo's editors pick September's most significant deals, including lucrative partnerships for Halozyme and the pursuit of Dimension Therapeutics. (Free article.)
When it comes to deal-making, In Vivo's editors have always been quick to single out transactions that we feel will spark trends or otherwise have a major impact on the life sciences industry. Below, an expandable timeline of the deals we chose as bellwethers for pharma and medtech in each year of this still-young century and what we said about them at the time. (Free article.)
In Vivo's editors pick August's most significant deals, including Gilead's acquisition of Kite and AstraZeneca's Parkinson's deals. (Free article.)
A sampling of data from In Vivo and the EBD Academy's comprehensive survey, Future-Proofing Human Capital In Global Life Sciences.
In Vivo's editors pick July's most significant deals, including AZ and Merck's oncology deal, and late-stage funding for Silk Road Medical. (Free article.)
In Vivo's editors pick June's most significant deals, including Idorsia's IPO and Medtronic's outcomes-based contract with Aetna. (Free article.)